What does the evidence say about Saffron Mood Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Saffron Mood Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - However, due to some potentially significant adverse events associated with its medicinal use at higher doses or prolonged administration, clinical monitoring should be considered. [Hasheminasab FS (2026); evidence level 1] - Background Crocus sativus L., commonly known as saffron, is a widely used spice with a rich history of culinary and medicinal applications. [Hasheminasab FS (2026); evidence level 1] - This systematic review aims to compile human data from studies on monopreparations of C. [Hasheminasab FS (2026); evidence level 1] - This literature review synthesises evidence from randomised controlled trials, meta-analyses, safety data, dosing patterns, proposed mechanisms, and guideline positioning regarding saffron in depression, with a focus on adult major depressive disorder and related depressive symptomatology. [Dimech L (2026); evidence level 4] - Across placebo-controlled trials in mild-to-moderate depression, saffron, most commonly administered at 30 mg per day for approximately six weeks, has been associated with clinically meaningful reductions in depressive symptom severity, typically measured using the Hamilton Depression Rating Scale (HAM-D). [Dimech L (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.